G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 earnings per share estimates for G1 Therapeutics in a report released on Monday, June 5th. HC Wainwright analyst E. White now forecasts that the company will earn $0.12 per share for the quarter, up from their previous estimate of $0.08. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for G1 Therapeutics’ FY2025 earnings at $0.61 EPS.
G1 Therapeutics (NASDAQ:GTHX – Get Rating) last issued its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.11. G1 Therapeutics had a negative return on equity of 222.92% and a negative net margin of 219.66%. The business had revenue of $12.95 million during the quarter, compared to analyst estimates of $10.54 million.
G1 Therapeutics Stock Performance
Shares of GTHX stock opened at $2.80 on Tuesday. The business has a 50 day simple moving average of $2.74 and a 200 day simple moving average of $4.38. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.57 and a quick ratio of 4.11. The firm has a market capitalization of $144.65 million, a price-to-earnings ratio of -1.01 and a beta of 1.92. G1 Therapeutics has a 12-month low of $2.38 and a 12-month high of $17.49.
Institutional Trading of G1 Therapeutics
A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of G1 Therapeutics by 5.6% in the first quarter. JPMorgan Chase & Co. now owns 2,149,526 shares of the company’s stock valued at $5,761,000 after purchasing an additional 113,904 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of G1 Therapeutics by 4.1% during the third quarter. Vanguard Group Inc. now owns 1,686,453 shares of the company’s stock worth $21,063,000 after acquiring an additional 65,952 shares in the last quarter. Millennium Management LLC raised its holdings in shares of G1 Therapeutics by 42.6% during the fourth quarter. Millennium Management LLC now owns 1,671,859 shares of the company’s stock worth $9,078,000 after acquiring an additional 499,363 shares in the last quarter. State Street Corp raised its holdings in shares of G1 Therapeutics by 1,038.1% during the third quarter. State Street Corp now owns 1,618,381 shares of the company’s stock worth $20,214,000 after acquiring an additional 1,476,175 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of G1 Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 1,519,657 shares of the company’s stock worth $18,980,000 after acquiring an additional 150,376 shares in the last quarter. Hedge funds and other institutional investors own 53.13% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Read More
- Get a free copy of the StockNews.com research report on G1 Therapeutics (GTHX)
- Is American Airlines a Good Stock to Buy?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- It Is Not Too Late To “Git” On Board With GitLab
- Is Frontline’s 20% Dividend Too Good To Be True?
- Hospitality’s Rebound Has A Table At Cracker Barrel
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
